TIzanidine for the Preventive Treatment of Episodic MigrainE (TIME)

PHASE3RecruitingINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 25, 2025

Study Completion Date

December 25, 2025

Conditions
Migraine Without AuraMigraine With Aura
Interventions
DRUG

Tizanidine Hydrochloride

Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks

DRUG

Tizanidine Hydrochloride

Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks

DRUG

Tizanidine Hydrochloride Placebo

Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

The Affiliated Hospital of Southwest Medical University, Luzhou

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

RECRUITING

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

RECRUITING

The First Hospital of Jiaxing, Jiaxing

ACTIVE_NOT_RECRUITING

Affiliated Hospital of Shaoxing University, Shaoxing

All Listed Sponsors
collaborator

Sichuan Credit Pharmaceutical Co., Ltd.

INDUSTRY

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER